Explain the treatment of adenosine deaminase deficiency by genetically engineered lymphocytes. Why is this treatment not permanent ?
Explain the treatment of adenosine deaminase deficiency by genetically engineered lymphocytes. Why is this treatment not permanent ?

Answer: SCID is identified in the first six months of life for the majority of people with ADA deficiency. These babies frequently do not live past the age of two if they are not treated. In roughly 10% to 15% of instances, the start of immunological deficiency is delayed (delayed onset) to between 6 and 24 months of age, or even into adulthood (late onset). Immune deficiency is less severe in these later-onset cases, resulting in recurrent upper respiratory and ear infections. Affected people may suffer persistent lung impairment, malnutrition, and other health issues over time.